Development of a highly efficient second generation nicotine-conjugate vaccine to treat nicotine addiction
US10004811B2 · kind B2 · utility
0Cited by
12References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 14, 2013 |
| Grant date | Jun 26, 2018 |
| Priority date | — |
| Expiry date | Mar 14, 2033 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/34
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention is directed to a conjugate which comprises an isolated adenovirus hexon protein coupled to nicotine or a nicotine analog, as well as a method of inducing an immune response against nicotine in a human by using the conjugate.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.